The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives
Abstract
The need for potentiating immune responses to recombinant or subunit antigens has prompted GlaxoSmithKline (GSK) Biologicals to develop various Adjuvant Systems for the design of prophylactic and therapeutic vaccines. Adjuvant Systems are formulations of classical adjuvants mixed with immunomodulators, specifically adapted to the antigen and the target population. They can activate the appropriate innate immune system and subsequently impact on adaptive immune responses. AS04 is an Adjuvant System that has demonstrated significant achievements in several vaccines against viral diseases. AS02, another Adjuvant System, is being evaluated in various contexts, where a strong T-cell response is needed to afford protection. Likewise, AS01 has been developed for vaccines where the induction of a yet stronger T-cell-mediated immune response is required. Altogether, the promising clinical results strongly support the concept of Adjuvant Systems and allow for further development of new vaccines, best adapted to the target population and the immune mechanisms of protection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The causal relation between human papillomavirus and cervical cancer
Bosch, F. X., Lorincz, A., Munoz, N., Meijer, C. J. L. M., & Shah, K. V. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.4.244 · Cited by 3,538
KIM, H. W., CANCHOLA, J. G., BRANDT, C. D., PYLES, G., CHANOCK, R. M., JENSEN, K., & PARROTT, R. H. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120955 · Cited by 1,981
Efficacy of BCG Vaccine in the Prevention of Tuberculosis: Meta-analysis of the Published Literature
Colditz, G. A. (1994) · JAMA · doi:10.1001/jama.1994.03510330076038 · Cited by 1,918
Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., De Carvalho, N. S., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17398-4 · Cited by 1,643
Harper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A.-B., Romanowski, B., Roteli-Martins, C. M., Jenkins, D., Schuind, A., Costa Clemens, S. A., & Dubin, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68439-0 · Cited by 1,632
Cooperation of Toll-like receptor signals in innate immune defence
Trinchieri, G., & Sher, A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2038 · Cited by 1,364
Paavonen, J., Jenkins, D., Bosch, F. X., Naud, P., Salmerón, J., Wheeler, C. M., Chow, S.-N., Apter, D. L., Kitchener, H. C., Castellsague, X., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60946-5 · Cited by 1,315
KAPIKIAN, A. Z., MITCHELL, R. H., CHANOCK, R. M., SHVEDOFF, R. A., & STEWART, C. E. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120954 · Cited by 1,033
Stoute, J. A., Slaoui, M., Heppner, D. G., Momin, P., Kester, K. E., Desmons, P., Wellde, B. T., Garçon, N., Krzych, U., Marchand, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360202 · Cited by 870
Self-citationGlycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes
Stanberry, L. R., Spruance, S. L., Cunningham, A. L., Bernstein, D. I., Mindel, A., Sacks, S., Tyring, S., Aoki, F. Y., Slaoui, M., Denis, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011915 · Cited by 794
Alonso, P. L., Sacarlal, J., Aponte, J. J., Leach, A., Macete, E., Milman, J., Mandomando, I., Spiessens, B., Guinovart, C., Espasa, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17223-1 · Cited by 752
Protective Effect of BCG against Tuberculous Meningitis and Miliary Tuberculosis: A Meta-Analysis
RODRIGUES, L. C., DIWAN, V. K., & WHEELER, J. G. (1993) · International Journal of Epidemiology · doi:10.1093/ije/22.6.1154 · Cited by 650
Modes of action of Freund's adjuvants in experimental models of autoimmune diseases
Billiau, A., & Matthys, P. (2001) · Journal of Leukocyte Biology · doi:10.1189/jlb.70.6.849 · Cited by 617
Bojang, K. A., Milligan, P. J., Pinder, M., Vigneron, L., Alloueche, A., Kester, K. E., Ballou, W. R., Conway, D. J., Reece, W. H., Gothard, P., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06957-4 · Cited by 528
GIANNINI, S., HANON, E., MORIS, P., VANMECHELEN, M., MOREL, S., DESSY, F., FOURNEAU, M., COLAU, B., SUZICH, J., & LOSONKSY, G. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.005 · Cited by 496
Self-citationSokal, E. M., Hoppenbrouwers, K., Vandermeulen, C., Moutschen, M., Léonard, P., Moreels, A., Haumont, M., Bollen, A., Smets, F., & Denis, M. (2007) · The Journal of Infectious Diseases · doi:10.1086/523813 · Cited by 426
Alonso, P. L., Sacarlal, J., Aponte, J. J., Leach, A., Macete, E., Aide, P., Sigauque, B., Milman, J., Mandomando, I., Bassat, Q., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67669-6 · Cited by 412
Waris, M. E., Tsou, C., Erdman, D. D., Zaki, S. R., & Anderson, L. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.2852-2860.1996 · Cited by 364
Tapping, R. I., Akashi, S., Miyake, K., Godowski, P. J., & Tobias, P. S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5780 · Cited by 353
Connors, M., Giese, N. A., Kulkarni, A. B., Firestone, C. Y., Morse, H. C., & Murphy, B. R. (1994) · Journal of Virology · doi:10.1128/jvi.68.8.5321-5325.1994 · Cited by 348
Skeiky, Y. A. W., Alderson, M. R., Ovendale, P. J., Guderian, J. A., Brandt, L., Dillon, D. C., Campos-Neto, A., Lobet, Y., Dalemans, W., Orme, I. M., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7618 · Cited by 313
The BCG Story: Lessons from the Past and Implications for the Future
Fine, P. E. M. (1989) · Clinical Infectious Diseases · doi:10.1093/clinids/11.supplement_2.s353 · Cited by 295
Kester, K. E., McKinney, D. A., Tornieporth, N., Ockenhouse, C. F., Heppner, D. G., Hall, T., Krzych, U., Delchambre, M., Voss, G., Dowler, M. G., et al. (2001) · The Journal of Infectious Diseases · doi:10.1086/318534 · Cited by 271
Reece, W. H. H., Pinder, M., Gothard, P. K., Milligan, P., Bojang, K., Doherty, T., Plebanski, M., Akinwunmi, P., Everaere, S., Watkins, K. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1009 · Cited by 264
Baldridge, J. R., McGowan, P., Evans, J. T., Cluff, C., Mossman, S., Johnson, D., & Persing, D. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.7.1129 · Cited by 256
Langermans, J. A. M., Doherty, T. M., Vervenne, R. A. W., Laan, T. V. D., Lyashchenko, K., Greenwald, R., Agger, E. M., Aagaard, C., Weiler, H., Soolingen, D. V., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2004.11.051 · Cited by 247
Pedersen, C., Petaja, T., Strauss, G., Rumke, H. C., Poder, A., Richardus, J. H., Spiessens, B., Descamps, D., Hardt, K., Lehtinen, M., et al. (2007) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2007.02.015 · Cited by 241
(How) do aluminium adjuvants work?
BREWER, J. (2006) · Immunology Letters · doi:10.1016/j.imlet.2005.08.002 · Cited by 236
Sun, P., Schwenk, R., White, K., Stoute, J. A., Cohen, J., Ballou, W. R., Voss, G., Kester, K. E., Heppner, D. G., & Krzych, U. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6961 · Cited by 232
Chiew Tong, N. K., Beran, J., Kee, S. A., Miguel, J. L., SanNchez, C., Bayas, J. M., Vilella, A., De Juanes, J. R., Arrazola, P., Calbo-Torrecillas, F., et al. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00689.x · Cited by 219
The Cycle of Human Herpes Simplex Virus Infection: Virus Transport and Immune Control
Cunningham, A. L., Diefenbach, R. J., Miranda‐Saksena, M., Bosnjak, L., Kim, M., Jones, C., & Douglas, M. W. (2006) · The Journal of Infectious Diseases · doi:10.1086/505359 · Cited by 203
New hepatitis B vaccine formulated with an improved adjuvant system
Kundi, M. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.2.133 · Cited by 193
Glenny, A. T., Buttle, G. A. H., & Stevens, M. F. (1931) · The Journal of Pathology and Bacteriology · doi:10.1002/path.1700340214 · Cited by 192
Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients
Atanackovic, D., Altorki, N. K., Stockert, E., Williamson, B., Jungbluth, A. A., Ritter, E., Santiago, D., Ferrara, C. A., Matsuo, M., Selvakumar, A., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.3289 · Cited by 184
Marchand, M., Punt, C. J. A., Aamdal, S., Escudier, B., Kruit, W. H. J., Keilholz, U., Håkansson, L., van Baren, N., Humblet, Y., Mulders, P., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00479-3 · Cited by 169
Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system
Thoelen, S., Damme, P. V., Matheï, C., Leroux-Roels, G. G., Desombere, I., Safary, A., Vandepapelière, P., Slaoui, M., & Meheus, A. (1998) · Vaccine · doi:10.1016/s0264-410x(97)00254-5 · Cited by 156
Klein, E., Kis, L. L., & Klein, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210240 · Cited by 155
Lalvani, A., Moris, P., Voss, G., Pathan, A. A., Kester, K. E., Brookes, R. H., Lee, E., Koutsoukos, M., Plebanski, M., Delchambre, M., et al. (1999) · The Journal of Infectious Diseases · doi:10.1086/315074 · Cited by 155
QS-21: a water-soluble triterpene glycoside adjuvant
Kensil, C. R., & Kammer, R. B. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.9.1475 · Cited by 152
Carl, R., Koulchin, V., Glenn, G. M., et al. (1995) · Immunological Reviews · doi:10.1111/j.1600-065x.1995.tb00075.x · Cited by 134
The use of oil adjuvants in therapeutic vaccines
Aucouturier, J., Ascarateil, S., & Dupuis, L. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.116 · Cited by 120
Garçon, N., Heppner, D. G., & Cohen, J. (2003) · Expert Review of Vaccines · doi:10.1586/14760584.2.2.231 · Cited by 118
Self-citationLiver transplantation in patients with HIV infection
Samuel, D., Duclos‐Vallée, J., Teicher, E., & Vittecoq, D. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00213-7 · Cited by 117
Khanna, R., Moss, D. J., & Burrows, S. R. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01328.x · Cited by 112
Stewart, V. A., McGrath, S. M., Dubois, P. M., Pau, M. G., Mettens, P., Shott, J. P., Cobb, M., Burge, J. R., LARSON, D. L., Ware, L. A., et al. (2007) · Infection and Immunity · doi:10.1128/iai.01879-06 · Cited by 103
Stewart, V. A., McGrath, S. M., Walsh, D. S., Davis, S. L., Hess, A. S., Ware, L. A., Kester, K. E., Cummings, J. F., Burge, J. R., Voss, G., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.033 · Cited by 102
Self-citationPolhemus, M. E., Magill, A. J., Cummings, J. F., Kester, K. E., Ockenhouse, C. F., Lanar, D. E., Dutta, S., Barbosa, A., Soisson, L. A., Diggs, C. L., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.03.012 · Cited by 98
Ockenhouse, C. F., Angov, E., Kester, K. E., Diggs, C. L., Soisson, L. A., Cummings, J. F., Stewart, A., Palmer, D. R., Mahajan, B., & Krzych, U. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.11.028 · Cited by 96
Goepfert, P., Tomaras, G. D., Horton, H., Montefiori, D. C., Ferrari, G., Deers, M., Voss, G., Koutsoukos, M., Pedneault, L., Vandepapelière, P., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.07.050 · Cited by 94
Alving, C. R., Richards, R. L., Moss, J., Alving, L. I., Clements, J. D., Shiba, T., Kotani, S., Wirtz, R. A., & Hockmeyer, W. T. (1986) · Vaccine · doi:10.1016/0264-410x(86)90005-8 · Cited by 91
Vantomme, V., Dantinne, C., Amrani, N., Permanne, P., Gheysen, D., Bruck, C., Stoter, G., Britten, C. M., Keilholz, U., Lamers, C. H. J., et al. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200403000-00006 · Cited by 88
Doherty, J. F., Pinder, M., Tornieporth, N., Carton, C., Vigneron, L., Milligan, P. J., Ballou, W. R., Holland, C. A., Kester, K. E., Voss, G., et al. (1999) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1999.61.865 · Cited by 87
Epstein, J. E., Charoenvit, Y., Kester, K. E., Wang, R., Newcomer, R., Fitzpatrick, S., Richie, T. L., Tornieporth, N., Heppner, D. G., Ockenhouse, C. F., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.01.031 · Cited by 79
Mooij, P., van der Kolk, M., Bogers, W. M. J. M., ten Haaft, P., van der Meide, P. H., Almond, N. M., Stott, J., Deschamps, M., Labbe, D., Momin, P., et al. (1998) · AIDS · doi:10.1097/00002030-199805000-00002 · Cited by 73
Evaluation of the Mtb72F Polyprotein Vaccine in a Rabbit Model of Tuberculous Meningitis
Tsenova, L., Harbacheuski, R., Moreira, A. L., Ellison, E., Dalemans, W., Alderson, M. R., Mathema, B., Reed, S. G., Skeiky, Y. A. W., & Kaplan, G. (2006) · Infection and Immunity · doi:10.1128/iai.74.4.2392-2401.2006 · Cited by 71
Pichyangkul, S., Gettayacamin, M., MILLER, R., Lyon, J. A., Angov, E., Tongtawe, P., RUBLE, D., HEPPNERJR, D., Kester, K. E., & Ballou, W. R. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.07.023 · Cited by 69
Voss, G., Manson, K. H., Montefiori, D. C., Watkins, D. I., Heeney, J. L., Wyand, M. S., Cohen, J., & Bruck, C. (2002) · Journal of Virology · doi:10.1128/jvi.77.2.1049-1058.2003 · Cited by 67
Pinder, M., Reece, W. H. H., Plebanski, M., Akinwunmi, P., Flanagan, K. L., Lee, E. A. M., Doherty, T., Milligan, P. J., Jaye, A., Tornieporth, N., et al. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2004.02371.x · Cited by 66
Moore, M. L., & Peebles, R. S. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.04.008 · Cited by 65
Withers, M., McKinney, D. A., Ogutu, B., Waitumbi, J., Milman, J., Apollo, O. J., Allen, O. G., Tucker, K., Soisson, L., Diggs, C., et al. (2006) · PLoS Clinical Trials · doi:10.1371/journal.pctr.0010032 · Cited by 65
Bourne, N., Milligan, G. N., Stanberry, L. R., Stegall, R., & Pyles, R. B. (2005) · The Journal of Infectious Diseases · doi:10.1086/498247 · Cited by 61
Tuberculosis vaccine development; from mouse to man
Reed, S. G., & Lobet, Y. (2005) · Microbes and Infection · doi:10.1016/j.micinf.2005.03.011 · Cited by 54
Vandepapelière, P., Rehermann, B., Koutsoukos, M., Moris, P., Garçon, N., Wettendorff, M. A., & Leroux-Roels, G. G. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.11.034 · Cited by 49
Self-citationPrince, G. A., Denamur, F., Deschamps, M., Garçon, N., Prieels, J., Slaoui, M., Thiriart, C., & Porter, D. D. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00417-5 · Cited by 49
Self-citationMacete, E., Aponte, J. J., Guinovart, C., Sacarlal, J., Ofori‐Anyinam, O., Mandomando, I., Espasa, M., Bevilacqua, C., Leach, A. J., Dubois, M., et al. (2006) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2006.01754.x · Cited by 48
Singh, M., Carlson, J. R., Briones, M., Ugozzoli, M., Kazzaz, J., Barackman, J., Ott, G., & O'Hagan, D. T. (1998) · Vaccine · doi:10.1016/s0264-410x(98)00179-0 · Cited by 47
Immunogenicity and Toxicity Testing of an Experimental HIV-1 Vaccine in Nonhuman Primates
Newman, M. J., WU, J.-Y., Coughlin, R. T., Murphy, C. I., Seals, J. R., Wyand, M. S., & Kensil, C. R. (1992) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1992.8.1413 · Cited by 39
Prince, G. A., Capiau, C., Deschamps, M., FABRY, L., Garçon, N., Gheysen, D., Prieels, J., Thiry, G., Opstal, O. V., & Porter, D. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.22.10287-10292.2000 · Cited by 37
Self-citationGall, S. A., Teixeira, J. C., Wheeler, C. M., Naud, P., Harper, D. M., Franco, E. L., Quint, W. G. V., Zahaf, T., Schuind, A., & Jenkins, D. (2007) · Cancer Research · Cited by 37
Garçon, N., Mechelen, M. V., & Wettendorff, M. A. (2006) · Elsevier eBooks · doi:10.1016/b978-012088403-2/50011-3 · Cited by 35
Self-citationGlycoprotein D adjuvant herpes simplex virus vaccine
Bernstein, D. I. (2005) · Expert Review of Vaccines · doi:10.1586/14760584.4.5.615 · Cited by 32
Cited by
Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901474 · Cited by 758
Self-citationToll-like receptors in immunity and inflammatory diseases: Past, present, and future
Vijay, K. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.03.002 · Cited by 643
Tseng, C.-T., Sbrana, E., Iwata-Yoshikawa, N., Newman, P. C., Garron, T., Atmar, R. L., Peters, C. J., & Couch, R. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035421 · Cited by 561
Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant
Casella, C. R., & Mitchell, T. C. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8228-6 · Cited by 560
Adjuvant system AS01: helping to overcome the challenges of modern vaccines
Didierlaurent, A. M., Laupèze, B., Di Pasquale, A., Hergli, N., Collignon, C., & Garçon, N. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2016.1213632 · Cited by 516
Self-citation
Metadata
- Authors
- Garçon, N., Chomez, P., & Van Mechelen, M.
- Venue
- Expert Review of Vaccines
- Publisher
- Informa UK Limited
- Published
- 2007-10-01
- Volume
- 6
- Issue
- 5
- Pages
- 723-739
- ISSN
- 1476-0584 (ISSN-L)
- 1744-8395
- OpenAlex
- W2000659418
- Cited by
- 476
- References
- 71
- FWCI
- 8.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.